Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Vitamin C  COVID-19 treatment studies for Vitamin C  C19 studies: Vitamin C  Vitamin C   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 15% Improvement Relative Risk Al Sulaiman et al. Vitamin C for COVID-19 LATE Is late treatment with vitamin C beneficial for COVID-19? PSM retrospective 284 patients in Saudi Arabia Lower mortality with vitamin C (not stat. sig., p=0.27) Al Sulaiman et al., Research Square, doi:10.21203/ Favors vitamin C Favors control
Ascorbic Acid as an Adjunctive Therapy in Critically Ill Patients with COVID-19: A Multicenter Propensity Score Matched Study
Al Sulaiman et al., Research Square, doi:10.21203/ (Preprint)
Al Sulaiman et al., Ascorbic Acid as an Adjunctive Therapy in Critically Ill Patients with COVID-19: A Multicenter Propensity.., Research Square, doi:10.21203/ (Preprint)
Apr 2021   Source   PDF  
  All Studies   Meta
Retrospective 158 critically ill patients receiving vitamin C and propensity matched controls, showing mortality OR 0.77 [0.48-1.23], and statistically significantly lower thrombosis, OR 0.42 [0.18-0.94]. 1000mg of vitamin C was given daily.
risk of death, 14.9% lower, RR 0.85, p = 0.27, treatment 46 of 142 (32.4%), control 59 of 142 (41.5%), NNT 11, odds ratio converted to relative risk, PSM.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Al Sulaiman et al., 2 Apr 2021, retrospective, propensity score matching, Saudi Arabia, preprint, 12 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin CAll
Abstract: Ascorbic Acid as an Adjunctive Therapy in Critically Ill Patients with COVID-19: A Multicenter Propensity Score Matched Study Khalid Al Sulaiman (  ) King Abdulaziz Medical City Ohoud Al Juhani King Abdulaziz University Khalid Bin Salah King Abdulaziz Medical City Hisham A. Badreldin King Abdulaziz Medical City Abdullah Al Harthi King Abdulaziz Medical City Mohammed Alenazi King Saud bin Abdulaziz University for Health Sciences Aisha Alharbi King Abdulaziz University Hospital Rahmah Algarni King Abdulaziz University Hospital Shmeylan Al Harbi King Abdulaziz Medical City Abdullah Alhammad King Saud University Ramesh Vishwakarma King Abdullah International Medical Research Center Sarah Aldekhyl King Abdulaziz Medical City Research Article Keywords: COVID-19, SARS-CoV-2, Ascorbic Acid, Vitamin C, Vitamins, Critically ill, Intensive Care Units (ICUs), 30-days ICU mortality Posted Date: April 2nd, 2021 Page 1/17 DOI: License:   This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 2/17 Abstract Background: Ascorbic acid represents an appealing option for clinicians to utilize in the context of a global health pandemic of COVID-19 patients due to its proposed clinical efficacy, relative safety, and low cost. Objectives: The aim of this study was to evaluate the efficacy and safety of using ascorbic acid in supplemental dose as adjunctive therapy in critically ill patients with COVID-19. Methods: This was a multi-center, non-interventional, retrospective cohort study. All critically ill adult patients admitted to ICU with a confirmed COVID-19 between March 1st to December 31st, 2020 were included in the final analysis. The study was conducted at two large governmental tertiary hospitals in Saudi Arabia. The purpose was to investigate the association between clinical outcomes with ascorbic acid use as an adjunctive therapy in COVID-19 after propensity score matching using baseline severity scores, systemic use of corticosteroids and study centers. Results: A 739 patients were included in this study; 296 patients were included after propensity score matching. There was no association between the administration of ascorbic acid and in-hospital mortality nor 30day ICU mortality (OR (95%CI): 0.77 (0.476, 1.234), p-value=0.2738 and OR (95%CI): 0.73 (0.438 ,1.204), p-value=0.215 respectively). Using ascorbic acid was associated with lower incidence of thrombosis compared with the non-ascorbic acid group (6.1% vs. 13% respectively); OR (95%CI): 0.42 (0.184, 0.937), p-value=0.0342). Conclusion: Supplemental dose of ascorbic acid as an adjunctive therapy in COVID19 critically ill patients was not associated with mortality benefits; but associated with lower incidence of thrombosis. Further studies are required to confirm these findings.
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop